

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 1 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|--|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Anaesthetics & Muscle Relaxants | | | | | | | | | | | | | |
| Alcuronium | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Bupivacaine | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ■ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Cisatracurium | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cyclobenzaprine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Desflurane | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dexmedetomidine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Enflurane | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ephedrine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Etidocaine | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ■ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Halothane | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Isoflurane | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ketamine | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ■ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Nitrous oxide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Propofol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Rocuronium | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sevoflurane | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sufentanil | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ■ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Suxamethonium (succinylcholine) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tetracaine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Thiopental | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tizanidine | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Vecuronium | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Analgesics | | | | | | | | | | | | | |
| Alfentanil | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ■ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Aspirin | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Buprenorphine | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ■ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Celecoxib | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ▲ | ◆ | ■ | ◆ | ◆ | ◆ |
| Codeine | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dextropropoxyphene | ▲ | ◆ | ◆ | ▲ | ◆ | ● | ◆ | ● | ▲ | ◆ | ◆ | ▲ | ▲ |
| Diamorphine (diacetylmorphine) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Diclofenac | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Dihydrocodeine | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fentanyl | ▲ | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ■ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Hydrocodone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Hydromorphone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ibuprofen | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Mefenamic acid | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Metamizole | ● | ● | ◆ | ● | ■ | ■ | ■ | ■ | ● | ■ | ● | ● | ● |
| Methadone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Morphine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nabumetone | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Naproxen | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Nimesulide | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Oxycodone | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ■ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Paracetamol (Acetaminophen) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pethidine (Meperidine) | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Piroxicam | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Remifentanyl | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tapentadol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tramadol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Antiarrhythmics | | | | | | | | | | | | | |
| Amiodarone | ▲ | ◆ | ◆ | ▲ | ■ | ● | ■ | ● | ▲ | ■ | ◆ | ▲ | ▲ |
| Bepidil | ◆ | ◆ | ◆ | ◆ | ■ | ● | ■ | ● | ◆ | ■ | ◆ | ◆ | ◆ |
| Digoxin | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ■ | ◆ | ◆ |
| Disopyramide | ◆ | ◆ | ◆ | ◆ | ■ | ● | ■ | ● | ◆ | ■ | ◆ | ◆ | ◆ |
| Dofetilide | ◆ | ◆ | ◆ | ◆ | ■ | ● | ■ | ● | ◆ | ■ | ◆ | ◆ | ◆ |
| Dronedarone | ◆ | ◆ | ▲ | ◆ | ■ | ● | ■ | ■ | ◆ | ■ | ■ | ◆ | ◆ |
| Flecainide | ◆ | ◆ | ◆ | ◆ | ■ | ● | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ |
| Lidocaine (Lignocaine) | ◆ | ◆ | ◆ | ◆ | ■ | ● | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Mexiletine | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ▲ | ◆ | ■ | ◆ | ◆ | ◆ |
| Propafenone | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ▲ | ◆ | ■ | ◆ | ◆ | ◆ |
| Quinidine | ▲ | ◆ | ◆ | ▲ | ■ | ● | ■ | ■ | ▲ | ■ | ◆ | ▲ | ▲ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 2 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|-------------------------------|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Antibacterials | | | | | | | | | | | | | |
| Amikacin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Amoxicillin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ampicillin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Azithromycin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Bedaquiline | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Capreomycin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cefalexin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cefazolin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cefepime | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cefixime | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cefotaxime | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ceftazidime | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ceftriaxone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Chloramphenicol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ciprofloxacin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Clarithromycin | ◆ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Clavulanic acid | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Clindamycin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Clofazimine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cloxacillin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cycloserine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dapsone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Delamanid | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Doxycycline | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ertapenem | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Erythromycin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Ethambutol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ethionamide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Flucloxacillin | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Gentamicin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Imipenem/Cilastatin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Isoniazid | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Kanamycin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Levofloxacin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Linezolid | ■ | ■ | ◆ | ■ | ◆ | ● | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Meropenem | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Metronidazole | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Moxifloxacin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nitrofurantoin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ofloxacin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Para-aminosalicylic acid | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Penicillins | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Piperacillin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pyrazinamide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Rifabutin | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Rifampicin | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Rifapentine | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Rifaximin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Spectinomycin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Streptomycin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sulfadiazine | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tazobactam | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Telithromycin | ◆ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Tetracyclines | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tinidazole | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Trimethoprim/Sulfamethoxazole | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Vancomycin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 3 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|---|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Anti-coagulant, Anti-platelet and Fibrinolytic | | | | | | | | | | | | | |
| Acenocoumarol | ▲ | ◆ | ◆ | ▲ | ■ | ■ | ■ | ● | ▲ | ■ | ◆ | ▲ | ▲ |
| Apixaban | ▲ | ◆ | ◆ | ▲ | ■ | ■ | ◆ | ■ | ▲ | ■ | ◆ | ▲ | ▲ |
| Argatroban | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Aspirin (anti-platelet) | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Betrixaban | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Clopidogrel | ▲ | ◆ | ◆ | ▲ | ◆ | ● | ◆ | ■ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Clopidogrel (recently stented patients) | ▲ | ◆ | ◆ | ▲ | ◆ | ● | ◆ | ● | ▲ | ◆ | ◆ | ▲ | ▲ |
| Dabigatran | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ |
| Dalteparin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dipyridamole | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Edoxaban | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ |
| Enoxaparin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fondaparinux | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Heparin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Phenprocoumon | ▲ | ◆ | ◆ | ▲ | ■ | ■ | ■ | ● | ▲ | ■ | ◆ | ▲ | ▲ |
| Prasugrel | ▲ | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Rivaroxaban | ▲ | ◆ | ◆ | ▲ | ■ | ■ | ◆ | ■ | ▲ | ■ | ◆ | ▲ | ▲ |
| Streptokinase | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ticagrelor | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ■ | ▲ | ◆ | ▲ | ▲ | ▲ |
| Tinzaparin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Warfarin | ▲ | ◆ | ◆ | ▲ | ■ | ■ | ■ | ● | ▲ | ■ | ◆ | ▲ | ▲ |
| Anticonvulsants | | | | | | | | | | | | | |
| Brivaracetam | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Carbamazepine | ▲ | ◆ | ◆ | ▲ | ■ | ■ | ■ | ● | ▲ | ■ | ■ | ▲ | ▲ |
| Clonazepam | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Eslicarbazepine | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Ethosuximide | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Gabapentin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lacosamide | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lamotrigine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Levetiracetam | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Oxcarbazepine | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Perampanel | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Phenobarbital (Phenobarbitone) | ▲ | ◆ | ◆ | ▲ | ■ | ■ | ■ | ● | ▲ | ■ | ■ | ▲ | ▲ |
| Phenytoin | ▲ | ◆ | ◆ | ▲ | ■ | ■ | ■ | ● | ▲ | ■ | ■ | ▲ | ▲ |
| Pregabalin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Primidone | ▲ | ◆ | ◆ | ▲ | ■ | ■ | ■ | ● | ▲ | ■ | ■ | ▲ | ▲ |
| Retigabine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Rufinamide | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ■ | ◆ | ◆ |
| Sultiame | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ◆ |
| Tiagabine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Topiramate | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ |
| Valproate (Divalproex) | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Vigabatrin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Zonisamide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 4 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|---------------------------|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Antidepressants | | | | | | | | | | | | | |
| Agomelatine | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Amitriptyline | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Bupropion | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Citalopram | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Clomipramine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Desipramine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Doxepin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Duloxetine | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Escitalopram | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fluoxetine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Imipramine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lithium | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Maprotiline | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Mianserin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Milnacipran | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Mirtazapine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nefazodone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Nortriptyline | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Paroxetine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Phenelzine | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Reboxetine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sertraline | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| St John's wort | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Tranlycypromine | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Trazodone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Trimipramine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Venlafaxine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Vortioxetine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Anti-diabetics | | | | | | | | | | | | | |
| Acarbose | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Canagliflozin | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Dapagliflozin | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Dulaglutide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Empagliflozin | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Exenatide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Glibenclamide (Glyburide) | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ |
| Gliclazide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ |
| Glimepiride | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ |
| Glipizide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ |
| Insulin | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Linagliptin | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Liraglutide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Metformin | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Nateglinide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ |
| Pioglitazone | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Repaglinide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ |
| Rosiglitazone | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Saxagliptin | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ |
| Semaglutide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Sitagliptin | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ |
| Tolbutamide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ |
| Vildagliptin | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 5 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|-----------------------|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Antifungals | | | | | | | | | | | | | |
| Amphotericin B | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Anidulafungin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Caspofungin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fluconazole | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ◆ |
| Flucytosine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Griseofulvin | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ■ | ◆ | ◆ |
| Isavuconazole | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ◆ |
| Itraconazole | ◆ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Ketoconazole | ◆ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ |
| Micafungin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Miconazole | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Nystatin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Posaconazole | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Terbinafine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Voriconazole | ◆ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Antihistamines | | | | | | | | | | | | | |
| Cetirizine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fexofenadine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Loratadine | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Antimalarials | | | | | | | | | | | | | |
| Amodiaquine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Artemether | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Artesunate | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Atovaquone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Chloroquine | ■ | ■ | ◆ | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ |
| Halofantrine | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ◆ | ◆ | ◆ | ▲ | ▲ |
| Hydroxychloroquine | ■ | ■ | ◆ | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ | ■ |
| Lumefantrine | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Mefloquine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Piperaquine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Primaquine | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Proguanil | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pyrimethamine | ■ | ■ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Quinine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sulfadoxine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 6 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|--|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Antipsychotics/Neuroleptics | | | | | | | | | | | | | |
| Amisulpride | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Aripiprazole | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Asenapine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Chlorpromazine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Clozapine | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Fluphenazine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Haloperidol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Iloperidone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Levomepromazine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lumateperone | ■ | ■ | ◆ | ■ | ◆ | ● | ◆ | ● | ■ | ◆ | ■ | ■ | ■ |
| Lurasidone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Olanzapine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Paliperidone | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Perazine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Periciazine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Perphenazine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pimozide | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pipotiazine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Quetiapine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Risperidone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sulpiride | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Thioridazine | ◆ | ◆ | ◆ | ◆ | ■ | ● | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Tiapride | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ziprasidone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Zotepine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Zuclophenthixol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Antivirals | | | | | | | | | | | | | |
| Aciclovir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Entecavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Oseltamivir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ribavirin | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Valaciclovir (Valacyclovir) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Anxiolytics/Hypnotics/Sedatives | | | | | | | | | | | | | |
| Alprazolam | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Bromazepam | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Buspirone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Chlordiazepoxide | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Clobazam | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Clorazepate | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Diazepam | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Estazolam | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Flunitrazepam | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Flurazepam | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Hydroxyzine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lorazepam | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lormetazepam | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Midazolam (oral) | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Midazolam (parenteral) | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Oxazepam | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Temazepam | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Triazolam | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Zaleplon | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Zolpidem | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Zopiclone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 7 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|---------------------------------|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Beta Blockers | | | | | | | | | | | | | |
| Atenolol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Bisoprolol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Carvedilol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Metoprolol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nebivolol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Oxprenolol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pindolol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Propranolol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sotalol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Timolol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Bronchodilators | | | | | | | | | | | | | |
| Acclidinium bromide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Aminophylline | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ◆ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Formoterol | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Glycopyrronium bromide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Indacaterol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ipratropium bromide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Montelukast | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Olodaterol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Roflumilast | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Salbutamol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Salmeterol | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Theophylline | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ◆ | ▲ | ◆ | ◆ | ▲ | ▲ |
| Tiotropium bromide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Umeclidinium bromide | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Vilanterol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Calcium Channel Blockers | | | | | | | | | | | | | |
| Amlodipine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Diltiazem | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Felodipine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nicardipine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Nifedipine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nisoldipine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nitrendipine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Verapamil | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 8 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|-------------------------|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Cancer Therapies | | | | | | | | | | | | | |
| Abemaciclib | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Abiraterone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Acalabrutinib | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Afatinib | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Alectinib | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Apalutamide | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Atezolizumab | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Bosutinib | ■ | ■ | ◆ | ■ | ◆ | ● | ◆ | ● | ■ | ◆ | ■ | ■ | ■ |
| Capecitabine | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Ceritinib | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Dasatinib | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Encorafenib | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Enzalutamide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Erlotinib | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fostamatinib | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Fulvestrant | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Gilteritinib | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ibrutinib | ■ | ■ | ◆ | ■ | ◆ | ▲ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Imatinib | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Ivosidenib | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Lenalidomide | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Midostaurin | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ■ | ■ |
| Neratinib | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nilotinib | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Olaparib | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Osimertinib | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Palbociclib | ■ | ■ | ◆ | ■ | ◆ | ▲ | ◆ | ▲ | ■ | ◆ | ■ | ■ | ■ |
| Pazopanib | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Pomalidomide | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Ribociclib | ■ | ■ | ▲ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Sotorasib | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Sunitinib | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Tamoxifen | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ■ | ◆ | ◆ |
| Venetoclax | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Vinblastine | ■ | ■ | ◆ | ■ | ▲ | ■ | ▲ | ■ | ■ | ▲ | ■ | ■ | ■ |
| Vincristine | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 9 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|---|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Contraceptives/HRT | | | | | | | | | | | | | |
| Desogestrel (COC) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Desogestrel (POP) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Drospirenone (COC) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Drospirenone (HRT) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dydrogesterone (HRT) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Estradiol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ethinylestradiol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Etonogestrel (implant) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Etonogestrel (vaginal ring) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Gestodene (COC) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Levonorgestrel (COC) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Levonorgestrel (emergency contrac.) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Levonorgestrel (HRT) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Levonorgestrel (implant) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Levonorgestrel (IUD) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Levonorgestrel (POP) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Medroxyprogesterone (depot injection) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Medroxyprogesterone (oral) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norelgestromin (patch) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norethisterone (COC) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norethisterone (HRT) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norethisterone (IM depot) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norethisterone (POP) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norgestimate (COC) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norgestrel (COC) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Norgestrel (HRT) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ulipristal | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Covid-19 Antiviral Therapies | | | | | | | | | | | | | |
| Bamlanivimab/Etesevimab | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Bebtelovimab | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Casirivimab/Imdevimab | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Favipiravir | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Molnupiravir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Niclosamide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nirmatrelvir + ritonavir (5 days) | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Nitazoxanide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Remdesivir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sotrovimab | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tixagevimab/Cilgavimab | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Covid-19 Host-directed Therapies | | | | | | | | | | | | | |
| Anakinra | ■ | ● | ◆ | ● | ◆ | ◆ | ◆ | ■ | ● | ◆ | ● | ● | ● |
| Baricitinib | ● | ■ | ◆ | ● | ◆ | ◆ | ◆ | ■ | ● | ◆ | ● | ● | ● |
| Budesonide (inhaled) | ◆ | ◆ | ■ | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Canakinumab | ● | ● | ◆ | ■ | ◆ | ◆ | ◆ | ■ | ● | ◆ | ● | ● | ● |
| Covid 19 convalescent plasma | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ |
| Covid-19 vaccines | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ |
| Dexamethasone (low dose) | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fluvoxamine | ◆ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ◆ |
| Hydrocortisone (oral or IV) | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Imatinib (14 days) | ■ | ■ | ◆ | ■ | ◆ | ▲ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Infliximab | ● | ● | ◆ | ● | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ● | ● | ● |
| Methylprednisolone (oral or IV) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Ruxolitinib | ● | ● | ◆ | ● | ◆ | ■ | ◆ | ■ | ● | ◆ | ■ | ● | ● |
| Sarilumab | ● | ● | ◆ | ● | ◆ | ◆ | ◆ | ■ | ● | ◆ | ● | ■ | ● |
| Tocilizumab | ● | ● | ◆ | ● | ◆ | ◆ | ◆ | ■ | ● | ◆ | ● | ● | ■ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 10 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|---|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Cystic Fibrosis Agents | | | | | | | | | | | | | |
| Ivacaftor | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ivacaftor/lumacaftor | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Ivacaftor/tezacaftor | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ivacaftor/tezacaftor/elexacaftor | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Gastrointestinal Agents | | | | | | | | | | | | | |
| Alosetron | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Antacids | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Bisacodyl | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Cimetidine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ◆ |
| Cisapride | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Esomeprazole | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Famotidine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lactulose | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Lansoprazole | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Loperamide | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Magnesium salts (oral) | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Mesalazine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Omeprazole | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pantoprazole | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Prucalopride | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Rabeprazole | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ranitidine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ◆ |
| Senna | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Gastrointestinal Agents (anti-emetics) | | | | | | | | | | | | | |
| Aprepitant | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Cyclizine | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dolasetron | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Domperidone | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dronabinol | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Granisetron | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Metoclopramide | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ondansetron | ◆ | ■ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Prochlorperazine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 11 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|--|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| HCV DAAs | | | | | | | | | | | | | |
| Elbasvir/Grazoprevir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ▲ | ◆ | ◆ |
| Glecaprevir/Pibrentasvir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ▲ | ◆ | ◆ |
| Ledipasvir/Sofosbuvir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ◆ |
| Ombitasvir/Paritaprevir/r | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Ombitasvir/Paritaprevir/r + Dasabuvir | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Sofosbuvir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sofosbuvir/Velpatasvir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sofosbuvir/Velpatasvir/Voxilaprevir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| HIV Antiretroviral Therapies | | | | | | | | | | | | | |
| Abacavir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Albuvirtide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Atazanavir alone | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Atazanavir + ritonavir | ◆ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Atazanavir/cobicistat | ◆ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Bictegravir/Emtricitabine/TAF | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cabotegravir (oral) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cabotegravir/rilpivirine (long acting) | ◆ | ◆ | ◆ | ◆ | ● | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Darunavir + ritonavir | ◆ | ◆ | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Darunavir/cobicistat | ◆ | ◆ | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Darunavir/Cobi/Emtricitabine/TAF | ◆ | ◆ | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Dolutegravir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dolutegravir/Lamivudine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dolutegravir/Rilpivirine | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dolutegravir/Abacavir/Lamivudine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Doravirine | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Doravirine/Lamivudine/Tenofovir-DF | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Efavirenz | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Elvitegravir/Cobi/Emtricitabine/TAF | ◆ | ◆ | ▲ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Elvitegravir/Cobi/Emtricitabine/TDF | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Emtricitabine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Emtricitabine/Tenofovir alafenamide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Emtricitabine/Tenofovir-DF | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Etravirine | ◆ | ◆ | ◆ | ◆ | ■ | ▲ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Fostemsavir | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ibalizumab-uyk | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lamivudine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lopinavir/ritonavir | ◆ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Maraviroc | ◆ | ◆ | ◆ | ◆ | ■ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nevirapine | ◆ | ◆ | ◆ | ◆ | ■ | ▲ | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Raltegravir | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Rilpivirine | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Rilpivirine/Emtricitabine/TAF | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Rilpivirine/Emtricitabine/TDF | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tenofovir-DF | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Zidovudine | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 12 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|--|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Hypertension / Heart Failure Agents | | | | | | | | | | | | | |
| Aliskiren | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ |
| Ambrisentan | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ |
| Amiloride | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Benazepril | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Bendroflumethiazide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Bosentan | ◆ | ◆ | ◆ | ◆ | ■ | ● | ■ | ● | ◆ | ■ | ■ | ◆ | ◆ |
| Candesartan | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Captopril | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Chlortalidone | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Cilazapril | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Clonidine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dopamine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Doxazosin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Enalapril | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Eplerenone | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Epoprostenol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Eprosartan | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fosinopril | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Furosemide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Hydralazine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Hydrochlorothiazide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Iloprost | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Indapamide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ▲ | ◆ | ■ | ◆ | ◆ | ◆ |
| Irbesartan | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Isosorbide dinitrate | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ivabradine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Labetalol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lacidipine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lercanidipine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lisinopril | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Losartan | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Macitentan | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Methyldopa | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Metolazone | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |
| Moxonidine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Olmesartan | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Perindopril | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Prazosin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Quinapril | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ramipril | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ranolazine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ▲ | ◆ | ◆ |
| Riociguat | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ■ | ◆ | ◆ |
| Sacubitril | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Selexipag | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sildenafil (PAH) | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sodium nitroprusside | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Spironolactone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tadalafil (PAH) | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Telmisartan | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Terazosin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Torasemide | ◆ | ◆ | ◆ | ◆ | ■ | ■ | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ |
| Trandolapril | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Treprostinil | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Valsartan | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Xipamide | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 13 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|-------------------------------------|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Illicit/Recreational | | | | | | | | | | | | | |
| Alcohol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Amphetamine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cannabis | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Carfentanil | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cocaine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ecstasy (MDMA) | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| GHB (Gamma-hydroxybutyrate) | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Heroin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| LSD (Lysergic acid diethylamide) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Methamphetamine | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Poppers (Amyl nitrate) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Immunosuppressants | | | | | | | | | | | | | |
| Adalimumab | ● | ● | ◆ | ● | ◆ | ◆ | ◆ | ■ | ● | ◆ | ● | ● | ● |
| Anti-thymocyte globulin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Azathioprine | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Basiliximab | ● | ● | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ● | ● |
| Belatacept | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Ciclosporin | ▲ | ■ | ◆ | ▲ | ■ | ■ | ◆ | ■ | ▲ | ◆ | ■ | ▲ | ▲ |
| Etanercept | ● | ● | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ● | ● |
| Everolimus | ◆ | ◆ | ◆ | ◆ | ▲ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Leflunomide | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Methotrexate | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Mycophenolate | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ |
| Pirfenidone | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sirolimus | ▲ | ◆ | ◆ | ▲ | ■ | ■ | ◆ | ■ | ▲ | ◆ | ■ | ▲ | ▲ |
| Tacrolimus | ▲ | ■ | ◆ | ▲ | ■ | ■ | ◆ | ■ | ▲ | ◆ | ■ | ▲ | ▲ |
| Tofacitinib | ● | ● | ◆ | ● | ◆ | ■ | ◆ | ◆ | ● | ◆ | ● | ● | ● |
| Voclosporin | ◆ | ■ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Inotropes & Vasopressors | | | | | | | | | | | | | |
| Adrenaline (Epinephrine) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dobutamine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Noradrenaline | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Vasopressin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lipid Lowering Agents | | | | | | | | | | | | | |
| Atorvastatin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Bezafibrate | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Clofibrate | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Evolocumab | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ezetimibe | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fenofibrate | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fish oils | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fluvastatin | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Gemfibrozil | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Lovastatin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pitavastatin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pravastatin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Rosuvastatin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ |
| Simvastatin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Multiple Sclerosis Agents | | | | | | | | | | | | | |
| Alemtuzumab | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Baclofen | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Cladribine | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Dantrolene sodium | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dimethyl fumarate | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fampridine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fingolimod | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Glatiramer acetate | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Natalizumab | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Ocrelizumab | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |
| Ozanimod | ■ | ■ | ◆ | ■ | ◆ | ■ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Peginterferon beta-1a | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Siponimod | ■ | ■ | ◆ | ■ | ■ | ● | ■ | ● | ■ | ■ | ■ | ■ | ■ |
| Teriflunomide | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ■ | ■ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |

Interactions with COVID-19 Host-directed Therapies*

*Licensed or under clinical investigation - please check regulatory status for your region

Charts updated 4 July 2022

Page 14 of 14

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

| | ANR | BAR | BUD | CAN | DXM | FLV | HC | IMA | IFX | MP | RUX | SAR | TCZ |
|-----------------------------------|-----|-----|-----|-----|-----|-----|----|-----|-----|----|-----|-----|-----|
| Other | | | | | | | | | | | | | |
| Acetylcysteine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Alendronic acid | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Alfuzosin | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Allopurinol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Calcium supplements | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Carbimazole | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Carbocisteine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Colchicine | ◆ | ◆ | ◆ | ◆ | ▲ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Dextromethorphan | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dihydroergotamine | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Donepezil | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Eltrombopag | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ergometrine (Ergonovine) | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ergotamine | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Finasteride | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Folic acid | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Guaifenesin | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Interferon beta | ■ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ■ | ■ | ◆ | ■ | ■ | ■ |
| Ivermectin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ◆ | ◆ |
| Levodopa | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Levothyroxine | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ■ | ◆ | ▲ | ◆ | ◆ | ◆ |
| Magnesium sulfate (IV) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Melatonin | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Memantine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Methylethergometrine | ◆ | ◆ | ◆ | ◆ | ◆ | ● | ◆ | ● | ◆ | ◆ | ◆ | ◆ | ◆ |
| Mirabegron | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Modafinil | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ■ | ■ | ◆ | ◆ |
| Potassium | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pramipexole | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Pyridostigmine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sildenafil (erectile dysfunction) | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Sulfasalazine | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ◆ |
| Tadalafil (erectile dysfunction) | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Tamsulosin | ◆ | ◆ | ◆ | ◆ | ◆ | ■ | ◆ | ■ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Steroids | | | | | | | | | | | | | |
| Beclometasone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Betamethasone | ◆ | ◆ | ◆ | ◆ | ■ | ▲ | ■ | ▲ | ◆ | ◆ | ■ | ◆ | ◆ |
| Budesonide (oral/rectal) | ◆ | ◆ | ■ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Ciclesonide | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Clobetasol | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Dexamethasone (full dose) | ◆ | ◆ | ◆ | ◆ | ■ | ▲ | ■ | ■ | ◆ | ■ | ■ | ◆ | ◆ |
| Fludrocortisone | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Flunisolide | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fluocinolone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Fluticasone | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Hydrocortisone (topical) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Megestrol acetate | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Methylprednisolone (topical) | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Mometasone | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Nandrolone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Oxandrolone | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Prednisolone | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Prednisone | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Stanozolol | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Testosterone | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |
| Triamcinolone | ◆ | ◆ | ◆ | ◆ | ◆ | ▲ | ◆ | ▲ | ◆ | ◆ | ◆ | ◆ | ◆ |

Key to abbreviations

| | | | | | |
|-----|---------------|-----|--------------------|-----|--------------------|
| ANR | Anakinra | FLV | Fluvoxamine | MP | Methylprednisolone |
| BAR | Baricitinib | HC | Hydrocortisone | RUX | Ruxolitinib |
| BUD | Budesonide | IMA | Imatinib (14 days) | SAR | Sarilumab |
| CAN | Canakinumab | IFX | Infliximab | TCZ | Tocilizumab |
| DXM | Dexamethasone | | | | |

Key to symbols

| | |
|---|--|
| ● | These drugs should not be coadministered |
| ■ | Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration |
| ▲ | Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required |
| ◆ | No clinically significant interaction expected |